Let’s face it, the market has no shortage of type 2 diabetes drugs and nobody is clamouring for a new one. Except, of course, if you are a large pharmaceutical giant like Novo Nordisk, the maker of Victoza.
Despite the worrying studies mentioned above, that the American Food and Drug Administration (FDA) gave Victoza the green light, dismissing all the safety warnings from their panel members.
One year later… surprise-surprise! FDA officials issued a warning, linking Victoza use to an increased risk of pancreatitis, thyroid cancer, and kidney failure.
The director of the FDA’s Office of Drug Evaluation was quick to explain why he dismissed the safety warnings. He started by noting the pressures on drug company executives to generate revenue. Then he added, “With most classes of drugs, there are similar drugs in development from competitors which places even more pressure to generate profit.”
So what? Drug safety goes on the back burner while drug company profits are pushed to the front? It’s beyond despicable that the head of drug evaluation candidly reveals how the focus on profits overrides safety.
But wait, it doesn’t end there… Novo Nordisk was so encouraged by this, that they moved ahead with even bigger plans. Recently, two trials have been completed that tested Victoza as an anti-obesity drug. In both trials, the Victoza dosage was significantly higher than the dosage given to diabetics. It should come as no surprise then that gastrointestinal adverse effects were also higher.
As if that is not bad enough, if a diabetes sufferer wants to do research about his or her condition online, they are more than likely going to end up on one of the most dangerous sites for anyone suffering with blood sugar issues: The American Diabetes Association (ADA) website.
You’d think the ADA is set up to help people, until you realise they receive MILLIONS from pharmaceutical companies. On the ADA website, I found a page titled “Our Corporate Sponsors.” And there they are, corporate logos and all! Here are some of the drug companies that donate at least a half million dollars per year to the ADA…
• Sanofi Aventis
• Novo Nordisk
As if that is not enough, the ADA advocates dietary choices that promote drug use.
On the website of Diabetes Forecast (the ADA magazine), I found an article titled, “Are Carbs the Enemy?”
And there it is — the smoking gun.
The article weighs the pros and cons of carb intake. And the question is “settled” with the observation that diabetes patients can eat their favourite foods in moderation. But that good news is qualified with this: “…as long as they lower their blood glucose with medication and exercise.”
Exercise? Absolutely. Control portions? Excellent advice!
Eat what you want and balance that with medication? APPALLING! (Unless you’re a Merck executive.)
You can find plenty of tips from nutritionist Martin Hum who shares his expert advice on how to successfully manage diabetes, on our dedicated blog The Real Diabetes Truth.
Bear in mind all the material in this email alert is provided for information purposes only. We are not addressing anyone’s personal situation. Please consult with your own physician before acting on any recommendations contained herein.
“$19 million paid to ADA by BigPharma?” Steve Cooksey, Diabetes Warrior, 2/8/11, diabetes-warrior.net
“Are Carbs the Enemy?” Tracey Neithercott, Diabetes Forecast, American Diabetes Association, forecast.diabetes.org
“Public Citizen to FDA: Pull Diabetes Drug Victoza From Market Immediately” Public Citizen press release, 4/19/12, citizen.org
“Cholesterol, Low” Thomas Cowan, M.D., Weston A Price Foundation, 8/9/05, westonaprice.org
“Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study” The Lancet, Vol. 358, No. 9279, 8/4/01, thelancet.com